metaPreg - Nifedipine (versus unexposed) during pregnancy

Nifedipine (versus unexposed)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.31 [0.39, 4.42]	-	1 study	36	51	not evaluable	ROB	-
Limb defects	2.04 [0.10, 39.95]	-	1 study	3	51	not evaluable	ROB	-
Major congenital malformations	2.07 [0.46, 9.35]	-	1 study	16	51	not evaluable	ROB	-
Oesophageal atresia with or without tracheo-oesophageal fistula	3.27 [0.98, 10.93]	-	1 study	221	9	not evaluable	ROB	-
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	7.18 [3.74, 13.80]	-	1 study	64	51	not evaluable	ROB	13.84 [6.94; .]
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine death (< 22 weeks)	2.48 [1.23, 4.99]	-	1 study	70	65	not evaluable	ROB	4.39 [1.76; .]
Late intrauterine deaths (> 22 weeks)	6.21 [1.52, 25.43]	-	1 study	9	65	not evaluable	ROB	11.90 [2.40; .]
Elective/induced termination of pregnancy	4.38 [2.10, 9.14]	-	1 study	41	76	not evaluable	ROB	8.22 [3.61; .]
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Hide endpoints reported in only one study ...